Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
155 hedge funds and large institutions have $716M invested in Aerie Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 54 increasing their positions, 47 reducing their positions, and 35 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 47
7% less funds holding
Funds holding: 167 → 155 (-12)
23% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 35
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
49% less capital invested
Capital invested by funds: $1.39B → $716M (-$677M)
85% less call options, than puts
Call options by funds: $819K | Put options by funds: $5.37M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$14.4M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$9.62M |
| 3 |
First Manhattan
New York
|
+$9.54M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$9.4M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$37.8M |
| 2 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$26.9M |
| 3 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$24.2M |
| 4 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$21.8M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$15.7M |
AERI Hedge Fund Activity: Q1 2020 in Review
155 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q1 2020, worth a combined $716M — down 49% from $1.39B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of AERI and 27 opened new positions — a net loss of 8 holders — while 47 trimmed existing stakes and 54 added.
The largest buyer was Deerfield Management, adding an estimated $14.4M. The largest seller was Foresite Capital Management III, cutting an estimated $37.8M.
- 155 institutional investors held Aerie Pharmaceuticals (AERI) as of Q1 2020, down from 167 in Q4 2019.
- Funds reported $716M of Aerie Pharmaceuticals stock for Q1 2020, down 49% quarter-over-quarter.
- 27 funds opened new Aerie Pharmaceuticals positions in Q1 2020 and 35 closed out, a net change of -8 holders.
- The largest Aerie Pharmaceuticals buyer in Q1 2020 was Deerfield Management, an estimated $14.4M added.
- The largest Aerie Pharmaceuticals seller in Q1 2020 was Foresite Capital Management III, an estimated $37.8M sold.
Based on aggregated 13F filings for Q1 2020.